LIDEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIDEX (LIDEX).
Glucocorticoid receptor agonist; inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokines and immune cell migration.
| Metabolism | Hepatic via CYP3A4; primarily excreted renally as metabolites. |
| Excretion | Renal (primarily as metabolites) ~ 95%; biliary/fecal ~5%. |
| Half-life | Terminal elimination half-life: 28-36 hours. Clinical context: Steady-state achieved in ~5-7 days; once-daily dosing maintains therapeutic levels without accumulation in patients with normal renal function. |
| Protein binding | ~99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Vd: 1-2 L/kg, suggesting extensive tissue distribution with partition into adipose tissue. |
| Bioavailability | Topical: Limited systemic bioavailability (<1% on intact skin though higher on damaged skin). Intralesional: 100% bioavailability into systemic circulation. |
| Onset of Action | Topical: Onset of anti-inflammatory effect within 1-2 hours. Intralesional: Faster onset, within minutes to 1 hour. |
| Duration of Action | Topical: Duration of effect after single application is 8-12 hours due to depot formation in stratum corneum. Intralesional: Duration up to 3-4 weeks due to slow release from injection site. |
| Molecular Weight | 494.54 |
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Use smallest amount effective; limit treatment duration to 2 weeks. Not recommended for children under 12 years due to higher risk of HPA axis suppression. |
| Geriatric use | Use with caution; apply smallest effective amount for shortest duration due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | LIDEX (fluocinonide) is not recommended during first trimester due to potential teratogenic effects; use only if clearly needed and benefit outweighs risk. |
| 2nd trimester | Caution in second trimester; avoid prolonged use, large areas, or occlusive dressings. Systemic absorption may cause fetal growth restriction if used extensively. |
| 3rd trimester | Avoid in third trimester due to risk of fetal adrenal suppression and low birth weight; minimal topical use may be considered under medical supervision. |
Clinical note
Comprehensive clinical and safety monograph for LIDEX (LIDEX).
| Placental transfer | Fluocinonide cross placenta via passive diffusion; degree is low with topical use but increases with extensive application or occlusive dressings. Systemically absorbed corticosteroid can reach fetal circulation. |
| Breastfeeding | Apply sparingly to small areas for short duration; avoid application to breast or nipple to prevent infant ingestion. Systemic absorption is minimal with proper use, but prolonged use on large areas may expose infant to corticosteroid side effects. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to fluocinonide or any componentUntreated bacterial, fungal, viral (e.g., herpes simplex, vaccinia) or parasitic skin infectionsRosaceaPerioral dermatitisCutaneous tuberculosis
| Precautions | Systemic absorption may cause reversible HPA axis suppression, Local irritation, atrophy, striae, and secondary infection, Use with caution in children and on face, intertriginous areas, Avoid prolonged use and occlusive dressings |
| Food/Dietary | No known food interactions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Topical corticosteroids, including LIDEX (fluocinonide), are generally considered low risk for teratogenicity when used as directed. However, systemic absorption can occur, especially with prolonged use, large areas, or occlusive dressings. First trimester: No well-controlled studies; animal studies show some risk with high systemic doses. Use only if potential benefit justifies risk. Second and third trimesters: Avoid prolonged or large area use; may cause fetal growth restriction or adrenal suppression if significant systemic absorption occurs. |
| Fetal Monitoring | Monitor for signs of systemic corticosteroid effects including adrenal suppression, Cushing's syndrome, hyperglycemia, and hypertension. In fetus/neonate, monitor for growth parameters if extensive maternal use. No routine fetal monitoring required for short-term, small-area use. |
| Fertility Effects | No known adverse effects on fertility with topical use. Systemic corticosteroids may impair spermatogenesis or ovulation, but topical fluocinonide at recommended doses is unlikely to affect fertility. |
| Lidex (fluocinonide) is a high-potency topical corticosteroid. Use for short-term treatment of steroid-responsive dermatoses. Avoid use on face, groin, axillae, or under occlusive dressings unless directed. Monitor for systemic absorption, especially in children, when used over large areas or for prolonged periods. Do not use for rosacea, perioral dermatitis, or bacterial/fungal infections. Taper use to prevent rebound flare. |
| Patient Advice | Apply a thin layer to affected area only, not more than prescribed amount. · Wash hands after application unless treating hands. · Do not cover with bandages or dressings unless instructed by your doctor. · Avoid contact with eyes, mouth, or mucous membranes. · Do not use on broken skin or infected areas unless told to. · Notify your doctor if condition worsens or does not improve after 2 weeks. · Do not use for other skin conditions without consulting your doctor. · Avoid abrupt discontinuation; taper as directed. |